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Abstract
Purpose: To determine whether severe hypoalbuminemia (<25 mg/L) has a significant effect on serum levels of vancomycin and
whether it can effect vancomycin dosage regimen and the loading dose administration.
Material and Methods: Prospective, cohort, and a single-center study included 61 patients whose vancomycin serum levels
were measured in steady state. Vancomycin trough levels (Cmin) that were in the range 15 to 20 mg/mL were considered ther-
apeutic and trough levels higher than 15 mg/mL were considered potentially nephrotoxic.
Results: In the group of patients with severe hypoalbuminemia, Cmin was significantly higher compared to the those with non-
severe hypoalbuminemia (>25 mg/L; 23.04 [19.14] vs 13.28 [11.28], P ¼ .01). In the group of patients who received the van-
comycin loading dose of 2 g, Cmin was significantly higher in patients with severe hypoalbuminemia compared to the patients with
nonsevere hypoalbuminemia (34.52 [25.93] vs 15.37 [10.48], P ¼ .04).
Conclusion: In critically ill septic patients with severe hypoalbuminemia, there is a high probability that the loading dose of
vancomycin is not necessary since it is associated with potentially toxic vancomycin Cmin, while in the patients with nonsevere
hypoalbuminemia the loading dose may be necessary to achieving therapeutic Cmin.
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Introduction
Treatment of sepsis in critically ill patients represents a big
challenge nowadays as most of these patients worldwide come
from countries that are underdeveloped or developing. It is
believed that 8 million patients die annually of the conse-
quences of sepsis, septic shock, and complications caused by
this multiple organ dysfunction syndrome. An additional prob-
lem in treatment of these patients lays in the fact that guidelines
for sepsis treatments are created in developed countries.1-4 On
the other hand, developing countries have a few adequately
functioning medical intensive care units (MICUs) and fully
trained critical care specialists, which further aggravates the
treatment of septic patients who are critically ill.5,6 Sepsis and
septic shock represent inadequate (too strong) response of the
organism to the presence of infection and all guidelines
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advocate that early use of antimicrobials is the cornerstone of
sepsis treatment.7 Adequate dosing of antibiotics is a major
challenge, especially in critically ill patients.8-10 Many factors
affect serum drug concentration and consequently the final
outcome. Serum albumin levels and renal and hepatic functions
significantly affect patient serum levels of antibiotics. Subther-
apeutic levels of antibiotics lead to inadequate treatment out-
comes and endanger lives of patients, while on the other hand,
increase antimicrobial resistance degree.11 One of antimicro-
bials frequently used in MICU is vancomycin, a glycopeptide
antibiotic that is effective in the treatment of infections caused
by gram-positive bacteria. Today, there are protocols that sug-
gest vancomycin dosing for the treatment of critically ill
patients and some of them recommend that vancomycin trough
serum levels (Cmin) should be in the range of 15 to 20 mg/mL, as
well as using the loading dose of 20 to 25 mg/kg to achieve it
more rapidly.12,13 Consulting a clinical pharmacist and intro-
ducing therapeutic drug monitoring (TDM) into the everyday
practice can improve treatment of critically ill patients in low-
resource countries.14 There are not enough studies reporting on
results of TDM of vancomycin or impact of hypoalbuminemia
on vancomycin serum levels in critically ill patients treated in
developing or underdeveloped countries, where regular TDM
of antimicrobials is not implemented. This study was created
with aims to determine vancomycin serum concentrations in
critically ill patients using standard dosage regimen with the
focus on defining the impact of hypoalbuminemia on vanco-
mycin serum levels. Besides this, the impact of implementing a
fixed loading dose to vancomycin serum levels was tested.
Methods
Study Design
This is a prospective, cohort, and single-center study performed
at the Medical Intensive Care Unit of the University Clinical
Center of the Republic of Srspka (MICU UCC RS) over a
1-year period. Measurement of Cmin was performed at the Insti-
tute for Laboratory Diagnostics UCC RS. Sampling of biolo-
gical material from the patients included in the study was
approved by the Ethical Committee of the UCC RS.
Population
The study included 61 patients who were treated at the MICU
UCC RS and who met the inclusion criteria.
Patients were eligible for inclusion if they all met the fol-
lowing criteria: (1) age 18 years, (2) with severe sepsis
(defined as presumed or confirmed infection with new-organ
dysfunction in the previous 48 hours), (3) treated by vancomy-
cin for less than 24 hours at the time of assessment, and (4) with
an expected ICU stay longer than 72 hours. Patients with end-
stage renal disease (estimated glomerular filtration rate <15
mL/min/1.73 m2 itself has been suggested as an endpoint)
and/or receiving renal replacement therapy were excluded from
the study.
Study Protocol
Patients were treated with 1 g of vancomycin every 12 hours.
A fixed vancomycin loading dose of 2 g was recommended by
a clinical pharmacist involved in morning rounds at MICU
since it was suitable for most patients. Patients weight cannot
be precisely measured at our clinic and average weight of
patients according to the anamnestic data was 78.11 kg. Given
the fact that the recommended vancomycin loading dose for
the treatment of critically ill patients is 25 to 30 mg/kg, the
loading dose of 2 g is in the range of 1937 to 2325 g, calcu-
lated for the average weight of studied patients (77.5 kg).
Physicians treating patients decided on whether vancomycin
loading dose should be administered. The following patient
data were collected from the medical charts and other medical
documentation: diagnosis, comorbidities, serum albumin lev-
els, platelets, serum creatinine, urea, bilirubin, aspartate ami-
notransferase, alanine aminotransferase, time of blood
sampling, and time of vancomycin administration.
Cockcroft-Gault formula was used for the estimation of crea-
tinine clearance (CrCL). Sampling of biological material was
performed using the following protocol:
1. The first blood sample (3-5 mL) was taken 30 minutes
before the fourth dose of vancomycin.
2. The second blood sample (3-5 mL) was taken 1 hour
after completion of vancomycin intravenous (IV)
infusion.
3. Both samples were sent to the Institute for Laboratory
Diagnostics 2 hours after sampling.
4. Samples were preserved at the Institute for Laboratory
Diagnostics at the temperature 0C to 5C.
It is considered that vancomycin trough serum levels were in
the therapeutic range if measured Cmin value was in the range
15 to 20 mg/mL.
Although there are only few data that show clear connection
between vancomycin serum levels and therapeutic efficacy or
toxicity, Infection Disease Society of America and American
Thoracic Society recommend that therapeutic range for Cmin is
15 to 20 mg/mL, since it is shown that the range recommended
by Geraci of 5 to 10 mg/mL cannot achieve area under the
curve/minimum inhibitory concentration (AUC/MIC) 400,
which is necessary for the isolates with MIC 1 mg/mL.15-17
When it comes to vancomycin toxicity, data are contra-
dictory since some studies show that vancomycin leads to
nephrotoxicity after its serum levels are above >10 mg/
mL.18,19 While other authors state that the risk of toxic renal
effects is increased with vancomycin serum levels above
15 mg/mL.20,21 Because of the fact that the serum concen-
tration of vancomycin 15 mg/mL is needed to achieve ther-
apeutic effect and that values over 15 mg/mL can cause
nephrotoxicity, TDM of vancomycin is preferred. However,
vancomycin TDM is rarely performed on regular basis in
developing countries.22
2 Dose-Response: An International Journal
Measurement of Vancomycin Plasma Concentrations
The measurement of vancomycin plasma concentrations
was performed using Cobas (Roche/Hitachi cobas c systems,
cobas c 501), with measuring range of 17 to 80 mg/L (1.2-55.2
mmol/L). The test is based on a homogenous enzyme technique
for quantitative analysis of vancomycin in human serum or
plasma. The principle of the test involves the competition
between the drug in the sample and the drug labeled with the
glucose-6-phosphate dehydrogenase (G6PDH) enzyme to bind
to the receptor sites on the antibody. Enzyme activity is
decreased by binding to the antibody, which allows determina-
tion of drug concentration in the sample by measuring enzy-
matic activity. The active enzyme converts the oxidized
nicotine amide dinucleotide (NAD) into NADH, resulting in
a change in spectrophotometrically measured absorption. The
process is not disturbed by the endogenous G6PDH since the
coenzyme reacts only with the bacterial (Leuconostoc mesen-
teroides) enzyme in the assay.
Statistical Analysis
Results are presented mainly using tables and graphs, and data
processing was performed by descriptive and comparative sta-
tistical methods. The results are expressed as mean (standard
deviation [SD]) for continuous variables and as numbers (per-
centages) for categorical variables. The data distribution was
analyzed by the Kolmogorov-Smirnov test. Comparisons
between continuous variables were performed using the Stu-
dent t test or the Mann-Whitney test, and categorical variables
were compared using the w2 test or the Fisher exact test as
appropriate. The P value <.05 was considered statistically sig-
nificant. Statistical analyses were performed using the SPSS 20
statistical program.
Results
Sixty-one patients were included in the study, of whom
36 (59%) were males, with mean (SD) weight 78.11 (17.63)
kg, mean (SD) height 175.07 (8.55) cm, and mean (SD) body
mass index (4.29). 25 (41%) patients were older than 65 years,
and 29 (47.5%) patients had 1 or more chronic comorbidities.
Mean SAPS II score (SD) of studied patients was 64.16 (14.27).
Table 1 shows the results of measured vancomycin Cmin,
relative to the serum creatinine concentration, CrCL, sex and
age structure, as well as the presence of chronic comorbidity.
The mean value (SD) of Cmin measured in 61 patients included
in the study was 17.28 (15.63). Vancomycin Cmin of 15 mg/mL
was considered borderline value for therapeutic efficacy, since
it is lower value of vancomycin serum therapeutic range (15-20
mg/mL). Accordingly, patients were divided into 2 groups,
patients with Cmin >15 mg/mL and patients with Cmin <15 mg/mL.
Of the total of 61 patients, 27 (44.3%) patients had Cmin
>15 mg/mL, while 34 (55.7%) patients had Cmin <15 mg/mL.
Table 2 shows the difference in individual demographic
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25 mg/L for severe hypoalbuminemia). Groups of patients with
severe hypoalbuminemia (<25 mg/L) were significantly older,
had significantly lower serum CrCL levels and significantly
higher serum creatinine levels. Using the Student t test for
small independent samples, significantly higher vancomycin
Cmin was found in the group of patients with severe hypoalbu-
minemia. This difference was retained even after excluding
from the analysis patients who had estimated CrCL <50 mL/
min, and even after additionally excluding patients who
received the loading dose of vancomycin. In this way, the effect
of renal function and the vancomycin loading dose on the
serum concentration of vancomycin was eliminated.
Table 3 shows the results of comparing vancomycin Cmin in
relation to severe hypoalbuminemia and the loading dose of
vancomycin. In the group of patients who received the loading
dose, statistically significant difference was detected between
patients with severe hypoalbuminemia and patients with non-
severe hypoalbuminemia.
Assessing the risk of renal insufficiency in patients with
vancomycin Cmin >15 mg/mL as a borderline trough toxic
value, it was found that a relative risk was significantly
increased in these patients (odds ratio [OR] ¼ 6.964, 95%
confidence interval [CI], 1.921-25.243). Assessing the risk of
vancomycin nephrotoxicity in patients with Cmax >45 mg/mL as
a borderline peak toxic value, it was found that the relative risk
was significantly increased in these patients (OR ¼ 2.380, 95%
CI, 0.720-7.869).
Discussion
Analyzing the obtained results, it is clear that patients with
severe hypoalbuminemia had higher vancomycin Cmin values,
especially those who received the loading dose of vancomycin.
In studied patients, severe hypoalbuminemia was associated
with age (>65 years), the presence of chronic comorbidity, and
higher values of urea and creatinine. In addition to this, it is
important to note that in the studied population desired thera-
peutic vancomycin serum levels (15mg/mL) were achieved in
only 27 (44.3%) patients.
Hypoalbuminemia is defined as the serum value of albumin
less than 35 mg/L, but severe or clinically significant hypoal-
buminemia is characterized with serum albumin lower than 25
mg/L.23,24 In hypoalbuminemia, which is common in critically
ill, there is a possibility of modification of volume of distribu-
tion (Vd) and CL of vancomycin, which is in moderately high
grade (55%) bounded to albumins.25 In the present study, all
Table 2. Patients’ Characteristics, Clinical Data and Vancomycin Cmin in Regard to Albumin Levels.
Albumin >25 mg/L, N ¼ 36 Albumin <25 mg/L, N ¼ 25 Difference (P Value)
Malea 21 (58.3) 15 (41.7) .89b
Age (years)c 52.64 (18.69) 63.92 (11.85) .01d
Weight (kg)c 77.22 (19.69) 79.40 (14.46) .64d
BMI (kg/m2)c 25.62 (4.35) 26.08 (4.27) .68d
Creatinine clearance (mL/min)c 95.34 (43.14) 72.39 (45.90) .05d
Serum creatinine (mmol/L)c 93.19 (50.25) 130.32 (98.59) .05d
Chronic comorbiditiesa 13 (44.8) 16 (55.2) .03b
Platelets (109/L)c 224.60 (125.77) 215.61 (168.79) .82d
AST (IU/L)c 98.77 (201.59) 56.67 (37.44) .43d
ALT (IU/L)c 105.12 (263.78) 38.71 (24.19) .33d
Bilirubin total (mmoL/L)c 19.54 (11.23) 21.20 (22.50) .75d
Bilirubin direct (mmoL/L)c 6.22 (4.53) 8.70 (11.05) .36d
Cmin
c 13.28 (11.28) 23.04 (19.14) .01d
Cmin, CrCL >50 mL/min
c 10.03 (8.21), (N ¼ 29) 19.05 (16.59), (N ¼ 15) .02d
Cmin, CrCL >50 mL/min, without vancomycin loading dose 8.93 (7.86), (N ¼ 20) 18.82 (18.55), (N ¼ 12) .04d






































Cmin, mean (SD) 34.52 (25.93) 20.17 (16.68) .14 15.37 (10.48) 12.37 (11.70) .47 15.37 (10.48) 34.52 (25.93) .04
Abbreviation: SD, standard deviation.
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patients had albumin serum levels less than 35 mg/L, and 41%
of them had severe hypoalbuminemia, or serum albumin values
less than 25 mg/L.
Comparing mean values of vancomycin Cmin between the
groups of patients with severe hypoalbuminemia and patients
with nonsevere hypoalbuminemia, significantly higher value of
Cmin in the group of patients with severe hypoalbuminemia was
found (P ¼ .01). This difference remains statistically signifi-
cant even after patients with CrCL <50 mL/min were elimi-
nated from the analysis (P ¼ .02). Vancomycin Cmin values in
the group of patients with severe hypoalbuminemia who
received the loading dose of vancomycin were significantly
higher than the desired serum values of 15 mg/mL.
In patients with severe hypoalbuminemia, vancomycin Cmin
is significantly higher in patients who received the loading dose
of vancomycin. Most studies advocate that toxic effect of van-
comycin appear when Cmin levels are above15 mg/mL.
26 The
vancomycin loading dose administration in patients with
severe hypoalbuminemia can potentiate toxic effects of vanco-
mycin; hence, its use in these groups of patients is questionable.
Similar results came from Mizuno et al who showed that severe
hypoalbuminemia in patients older than 75 years significantly
prolongs vancomycin elimination time (P ¼ .049), and it
increases the number of patients whose AUC/MIC was higher
than 450 mg  h/mL (P < .001). Values of Cmin and Cmax were
higher in patients with severe hypoalbuminemia, but this dif-
ference did not reach statistical significance. Besides, in
patients who had AUC/MIC higher than 450 mg  h/mL, higher
rate of nephrotoxicity was detected (P < .001).24
The vancomycin loading dose of 25 to 30 mg/kg is recom-
mended for rapid achievement of therapeutic serum concentra-
tions, especially in critically ill patients where increased Vd is
expected (sepsis, septic shock, burns, or administration of high
volume of IV fluids). After analyzing the results, it becomes
clear that the mean value of vancomycin Cmin in patients with
severe hypoalbuminemia who received the vancomycin load-
ing dose is significantly higher than borderline Cmin for vanco-
mycin toxicity. On the other hand, patients with severe
hypoalbuminemia who did not receive the vancomycin loading
dose had vancomycin Cmin values in reference range.
In patients with non-severe hypoalbuminemia, administra-
tion of the vancomycin loading dose led to achieving thera-
peutic serum concentrations of vancomycin in the steady
state, while patients who did not receive the vancomycin
loading dose had subtherapeutic vancomycin serum concen-
trations. Since literature data on influence of hypoalbumine-
mia and the vancomycin loading dose on vancomycin Cmin in
critically ill patients are scarce, comparing results with other
studies is not possible.
Analyzing the results of this study, it can be noted that out of
61 patients included in this study, only 27 (44.3%) had vanco-
mycin Cmin >15 mg/mL, while 34 (55.7%) patients had vanco-
mycin Cmin <15 mg/mL. Reasons for these results can be found
in the fact that small number of patients received the vanco-
mycin loading dose. Similar results were presented by Obara
et al who found that only 40% of ICU patients treated with
vancomycin reach therapeutic serum concentrations.27 Reasons
for this can be found in the absence of the vancomycin loading
dose and the lack of TDM on a regular basis.28
Physicians indicated the vancomycin loading dose of 2 g in
16 (26.2%) patients, while it was not indicated in 45 (73.8%)
studied patients. Truong et al investigated the influence of the
vancomycin loading dose of 2 g and if changing the previous
practice in ICU, which meant administering the vancomycin
loading dose to patients for whom physicians considered to be
necessary (younger patients, complicated disease, patients
without renal disease) would more rapidly achieve the thera-
peutic concentrations of vancomycin in the serum of critically
ill patients. It was shown that vancomycin Cmin was signifi-
cantly higher in patients who received the vancomycin loading
dose (14.9 [6.3] mg/mL vs 9.8 [6.6] mg/mL, P ¼ .001). After
introducing the practice of administering the vancomycin load-
ing dose in the ICU, 33% therapeutic vancomycin concentra-
tions were reached, compared to only 13% in the previous
period.29 Kitzis and Goldstein presented that administration
of the vancomycin loading dose of 15 mg/kg led to signifi-
cantly higher serum vancomycin concentrations compared to
administration of the vancomycin loading dose of 500 mg (19.1
[7.4] mg/mL vs 10.4 [2.7] mg/mL; P < .001),30 while Wang et al
showed that administration of the vancomycin loading dose of
25 mg/kg led to therapeutic but potentially toxic vancomycin
serum concentrations of 26.4 (9.3) mg/mL, which was detected
1 hour after completing vancomycin infusion.31,32
This study was impaired by several limitations. First, the
results are extracted from a single-center study conducted in
a specific, relatively small population of nonsurgical ICU
patients without renal impairment, thus not generalizable to all
critical care settings. In addition, variation of pharmacokinetic
parameters over time may also have influenced serum vanco-
mycin concentrations over time. Clinical outcomes were not
assessed since it was difficult to exclude the influence of many
other parameters, and MICUs were not available; hence, we
presumed certain serum concentrations of vancomycin to be
therapeutic, based on the literature data.
From the results obtained in this study, it can be concluded
that in septic, critically ill patients with severe hypoalbumine-
mia, administration of the vancomycin loading dose can lead to
potentially toxic serum concentrations. On the other hand, in
patients with nonsevere hypoalbuminemia, the vancomycin
loading dose administration led to achieving therapeutic serum
concentration of vancomycin. Vancomycin TDM is needed in
treatment of critically ill patients in order to achieve optimal
treatment goals.
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